Cameron D J, O'Brien P
Cancer. 1982 Aug 1;50(3):498-502. doi: 10.1002/1097-0142(19820801)50:3<498::aid-cncr2820500319>3.0.co;2-w.
Monocyte derived macrophages were isolated from the peripheral blood of 66 patients with either breast, colon, gynecological or hematological cancers. The macrophages from the breast and gynecologic cancer patients generally did not acquire enhanced cytotoxicity for human tumor cells after incubation with bacterial lipopolysaccharide (LPS). However, when the macrophages isolated from colon and hematologic cancer patients were studied, more than 50% of these patients possessed cytotoxic macrophages. LPS induced macrophage mediated cytotoxicity was also found to be inhibited by factors present in many cancer patient's plasma. Twenty-three of the 50 cancer patients studied possessed a plasma inhibitor capable of suppressing macrophage mediated cytotoxicity by more than 50%. Furthermore, of these 50 patients, 47 were incapable of killing the tumor cells in vitro either because they possessed nonresponsive macrophages and/or they possessed a plasma inhibitory factor. Thus, although macrophage cytotoxic function may be normal in some patients with cancer, cytotoxicity may be inhibited in some patients by factors in autologous plasma thereby rendering the macrophages ineffective in vivo.
单核细胞衍生的巨噬细胞从66例患有乳腺癌、结肠癌、妇科癌症或血液系统癌症患者的外周血中分离出来。乳腺癌和妇科癌症患者的巨噬细胞在与细菌脂多糖（LPS）孵育后，通常不会获得对人类肿瘤细胞增强的细胞毒性。然而，当研究从结肠癌和血液系统癌症患者中分离出的巨噬细胞时，超过50%的这些患者拥有细胞毒性巨噬细胞。LPS诱导的巨噬细胞介导的细胞毒性也被发现受到许多癌症患者血浆中存在的因子的抑制。在研究的50例癌症患者中，有23例拥有一种血浆抑制剂，能够将巨噬细胞介导的细胞毒性抑制超过50%。此外，在这50例患者中，47例在体外无法杀死肿瘤细胞，要么是因为他们拥有无反应性的巨噬细胞和/或他们拥有一种血浆抑制因子。因此，尽管巨噬细胞的细胞毒性功能在一些癌症患者中可能是正常的，但在一些患者中，细胞毒性可能会被自体血浆中的因子抑制，从而使巨噬细胞在体内无效。
